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Abstract
Recent advances in imaging studies and treatment approaches have greatly 
improved our knowledge about Giant Cell Arteritis (GCA). Previously thought of 
as a predominantly cranial disease, we now know that GCA is a systemic disease 
that may involve other medium and large vessel territories. Several imaging studies 
have shown that between 30 and 70% of patients with GCA present with large-
vessel vasculitis. Moreover, a significant proportion of patients present large-vessel 
disease in the absence of cranial involvement. Extra-cranial disease also poses 
management challenges as these patients may have a more refractory-relapsing 
disease course and need additional therapies. Aortic dilation and aneurysms are 
well-described late complications of GCA involving the large artery territories. In 
this chapter, we discuss the clinical picture of extra-cranial involvement in GCA, 
focusing on improved diagnostic protocols and suitable treatment strategies.
Keywords: giant cell arteritis, large-vessel vasculitis, polymyalgia rheumatica, 
vasculitis, diagnostic imaging
1. Introduction
Giant cell arteritis (GCA) is a systemic vasculitis that predominantly involves 
large and medium-size arteries [1]. It occurs almost exclusively in subjects aged 
50 years or older, and is the most common form of systemic vasculitis among the 
elderly [2]. GCA is more common among caucasian female patients, with a female–
male ratio of about 2–3:1. The GCA annual incidence varies with geographical 
location and ranges from 1.6 to 32.8 cases/100000 persons ≥50 years of age [3].
GCA is commonly defined as Large-Vessel (LV) GCA if the aorta and its 
branches are involved. The systemic nature of the disease was noted as early as the 
first cases described by Horton and colleagues in 1932 [4]. Later on, Gilmour sug-
gested that the disease should be called “giant-cell chronic arteritis” as the temporal 
arteritis appeared to be only part of a more widespread vascular disease [5]. Despite 
this early reports, physicians have mainly focused on typical cranial symptoms and 
visual disturbances and have relied mostly on temporal biopsy for diagnosis. This 
focus is well reflected in the 1990 ACR classification criteria that emphasised the 
importance of headache as a cardinal symptom and temporal biopsy as its primary 
diagnostic tool [6]. Unfortunately, the concept of GCA as a limited cranial disease is 
inaccurate and obscures essential clinical features. Furthermore, the misuse of clas-
sification criteria for diagnostic purposes, may lead to underdiagnose LV-GCA [7].
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In recent years there has been an increased awareness of the systemic large-
artery nature of GCA. Necropsy studies have shown histologic evidence of systemic 
large-artery vasculitis in approximately 80% of patients [8, 9]. Recent advances 
in diagnostic imaging techniques have confirmed these figures, suggesting that 
imaging will have an increasing impact in the diagnosis and management of GCA. 
[10–14]. Furthermore, patients with GCA are at increased risk of developing aortic 
dilation and aneurysms among other complications [15–17].
Altogether, these issues highlight the importance of the extra-cranial involve-
ment of GCA which has been under-recognised and poorly managed.
2. Pathophysiology
GCA is an idiopathic inflammatory granulomatous vasculitis. The aetiology is 
unknown, and most probably, genetic, environmental, vascular, and age-related 
factors concur to the development of the disease [2, 18]. In GCA, a lymphocyte and 
plasma cell infiltrate originates at the vasa vasorum in the adventitia of large vessels, 
which then penetrates the vessel wall leading to an intimal and media hyperplasia 
and vessel wall thickening [19]. Multinucleated giant cells form a complex near the 
intima-media complex, but they are not a requisite for diagnosis. Inflammation can 
be segmental, circumferential, or transmural [9, 20]. The predominance of GCA 
by some vessel territories and the mechanisms behind the different phenotypes like 
LV-GCA are still unsolved questions. In fact, most studies have been performed in 
temporal artery biopsies, as large arteries are not as readily accessible for histologic 
examination. Animal models also present limitations regarding the expression of 
the disease in different vascular territories. The interaction of immunopathogenic 
mechanisms with the different functional and anatomic characteristics of the vessel 
walls in different parts of the body may explain the distinct aspects of LV-GCA 
pathophysiology.
2.1 Immunologic mechanisms in large vessel giant cell arteritis
The critical event in initiating and sustaining the inflammatory response is 
thought to be the abnormal maturation and loss of tolerance of vascular Ddendritic 
cells (DCs), which is triggered by toll-like receptors (TLRs) [21, 22]. Differentiated 
DCs drive T cell and macrophage recruitment [21]. Upon the maturation of DCs, 
CD4+ T cells are also stimulated by local cytokines, such as IL12, to polarise into 
T-helper 1 (Th1) and IL6 and IL23 to polarise into Th17 cells [23].
TH17 cells are responsible for implementing a strong acute IL17 mediated 
inflammatory response, which leads to the overproduction of a cluster of cytokines, 
namely IL1β, IL6, IL23 and TNF-α [23]. Type II cytokine receptors (mainly IL6 and 
IL1β) signal through JAK1 homo-dimers [24] promoting further cellular activation 
and inflammatory response. The IL17 pathway is therefore responsible for most of 
the inflammatory response in the acute phase and explains the systemic nature of 
the disease [25, 26].
Th1 cells differentiation induces an immune response where IFN-γ is the central 
cytokine [27]. IFN-γ receptor signals through JAK1–JAK2 heterodimers [28]. The 
INF-γ signature further enhances the inflammatory response (through IL1β, IL6, 
and TNF-α), leading to macrophage differentiation and activation. Upon the stimu-
lation by the granulocyte-macrophage colony-stimulating factor (GM-CSF) pro-
duced by T cells, macrophages act in sustaining inflammation and are key players in 
the interaction with the stromal and extracellular matrix [29, 30]. This interaction 
is mediated by matrix metalloproteinases (MMP) and several growth factors. 
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MMP are proteases with elastolytic activity, released and activated by inflamma-
tory cells. Smooth muscle loss and proteolytic imbalance may contribute to elastic 
fibre rupture, weakening of the artery wall, and cell migration [29, 31]. The IFN-γ 
signature is responsible for the histiocytic reaction, myofibroblast differentiation, 
intimal hyperplasia, neoangiogenesis, vascular remodelling, damage, and fibrosis 
[32]. These aspects explain the vascular manifestations and the LV complications 
of GCA. Current treatments efficiently inhibit the Th17-mediated response, but 
not the Th1 mediated expression of IFN-γ [27, 33]. Thus, the current management 
of vascular manifestations like artery stenosis and aneurysms is suboptimal, as 
vascular remodelling processes may subsist even in the absence of raised inflamma-
tory markers [34].
Patients with polymyalgia rheumatica (PMR) present activated DCs in focal 
vessel infiltrates with the expression of inflammatory cytokine production (IL1β 
and IL6), but IFN-y is absent [35]. Therefore, it is thought that it is the IFN-γ path-
way, and not IL17 activation that marks the progression to overt vascular inflamma-
tion and remodelling.
It is not yet clear why some patients have only PMR while others progress to 
periadventitial or transmural vasculitis. Different TLR expression on DCs may 
partly explain such patterns as TLR4 activation induces transmural panarteritis, 
while TLR5 ligands promote adventitial perivasculitis [36]. Moreover, DCs exhibit 
distinct combinations of TLRs in different vascular beds [37]. Thus, the phenotype 
of the vasculitis may depend upon the profile of the TLR driven T cell activation, 
which is specific of each vascular territory.
The interaction between T cells and B cells might also be implicated in the 
expression of LV-GCA. Recent findings in aorta tissue samples from 9 LV-GCA 
patients who underwent aortic aneurysm surgery, showed massive infiltration of 
B-cells, which outnumbered T-cells. B-cells were mainly found in the adventitia and 
were organised into tertiary lymphoid organs [38]. This is an uncommon observa-
tion in temporal artery biopsies.
The interaction of immune mechanisms and the vascular matrix is also demon-
strated by the MMP expression in singular vascular fields. MMP2 tissue expression 
was observed in active temporal artery lesions and in aortic aneurysm samples 
obtained in 2 GCA patients. However, MMP9 was present only in temporal artery 
lesions and faintly detectable in normal temporal arteries and GCA-related aneu-
rysms [17]. While MMP9 is mainly produced by inflammatory cells, MMP2 may 
also be expressed in smooth muscle cells and be involved in reparative mechanisms. 
Therefore, the expression of MMPs on different vascular beds may also impact on 
the clinical features of GCA.
2.2 Atherosclerosis, ageing and large vessel vasculitis
Atherosclerosis is highly prevalent among GCA patients as it is most present at 
an advanced age. The coexistence of these two diseases and the underlying immune 
mechanisms of both may tailor the phenotype of the vasculitis. It is known that 
patients with cardiovascular risk factors have a higher risk of developing severe 
ischaemic manifestations of GCA [39]. In fact, patients with ischemic complications 
have lower expression of IL6 suggesting that IL6 may play a protective angiogenic 
role to compensate for ischemia [40]. Furthermore, at the supra-aortic level, 
atherosclerosis most commonly affects the carotids, while LV-GCA predominantly 
affects the axillary arteries. Regardless of the immune profile, age and genetic 
factors also influence the development of atherosclerosis. In caucasians, atheroscle-
rosis occurs later and less extensively in intracranial arteries compared to extra-
cranial arteries. Interestingly, Asian and African populations are more affected by 
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intracranial atherosclerosis and also show a low prevalence of cranial GCA [3, 41]. 
Thus, atherosclerosis may alter vessel vulnerability or expression of GCA.
Age is an important factor that affects vascular and immune processes with a 
possible impact on disease vulnerability and manifestations [42]. Ageing induces 
significant changes in the expression of vascular MMP2 and MMP9 and reduces 
arterial smooth muscle proliferative capacity [43–45]. One of the main distinctions 
between LV-GCA and Takayasu arteritis (TAK) has been attributed to an age cut-
off. Interestingly, TAK shows similar immunologic mechanisms with dysregulated 
activation of Th1 and Th17 pathways [46] and therefore age-related factors may be 
the key to explain the distinct manifestations between LV-GCA and TAK [20, 42].
3. Clinical features of large vessel giant cell arteritis
3.1 Clinical manifestations
LV-GCA usually presents with prominent constitutional symptoms and a 
marked increase in inflammatory markers. Systemic constitutional symptoms 
include fever, malaise, weight loss and night sweats. Symptoms are usually non-
specific and, in up to 20% of the patients, systemic constitutional symptoms are the 
only clinical features of the disease with some cases being diagnosed following an 
investigation for fever of unknown origin [10, 18]. Aortitis is a common feature in 
LV-GCA. Aortitis is often pauci-symptomatic, but some patients may refer chest or 
back pain [18]. LV-GCA also affects the main arteries of the limbs, presenting most 
commonly as limb claudication. Limb claudication reflects intimal and muscular 
hyperplasia secondary to vascular inflammation, which leads to vessel wall thicken-
ing with lumen occlusion. Limb claudication involves the arms more frequently 
than the legs and may be present in up to 50% of LV-GCA patients. It can be inter-
mittent and asymmetric despite vascular involvement being bilateral in around 
80% of the patients [7, 10, 47].
The preferred vascular territories involved are the supra-aortic branches, 
particularly the axillary and subclavian arteries, which are involved in almost all 
patients with LV-GCA. Carotid and vertebral artery involvement are less frequent. 
Aortitis is present in around 50–65% of the patients with documented LV-GCA. 
Most commonly, it involves the aortic arch and the thoracic descending aorta. When 
the abdominal aorta is affected, there is usually involvement of the thoracic seg-
ment as well. Femoral arteries and inferior limb arteries are involved in only around 
10–15% of the patients. Sometimes differential diagnosis with atherosclerosis, 
very commonly found in these arteries, may be difficult. Visceral arteries are rarely 
affected. [7, 10, 12, 47–49].
3.2  Clinical overlap between large vessel vasculitis, cranial giant cell arteritis 
and polymyalgia rheumatica
There is a considerable clinical and epidemiologic overlap between GCA 
and PMR. PMR is a clinical syndrome characterised by bilateral shoulder pain, 
morning stiffness, shoulder or pelvic girdle weakness, and peripheral arthralgia/
arthritis [2]. Approximately 20% of PMR patients have GCA, whereas PMR is 
present in up to 60% of GCA patients [2, 50, 51]. PMR is also the main form 
of relapse in up to 50% of GCA patients, while cranial symptoms are relatively 
uncommon at relapse [52]. Interestingly, Positron Emission Tomography (18FDG-
PET) LV fluorodeoxyglucose increased uptake was noted in 30% of patients with 
isolated polymyalgia rheumatica at diagnosis [53]. Therefore, PMR patients with 
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incomplete response to corticosteroid treatment or a relapsing disease should be 
re-evaluated for LV involvement.
Patients with LV-GCA are more frequently women and present at a younger 
age, whereas patients with cranial GCA are usually men and older [7, 10, 54]. When 
compared with cranial GCA, patients with LV-GCA present less frequently with 
headache (35% in LV-GCA vs. 60% in cranial GCA), jaw claudication (22% in LV-GCA 
vs. 50% in cranial GCA) and also with fewer cranial ischemic symptoms (permanent 
visual loss in 4% in LV-GCA vs. 20% in cranial GCA) [10, 55–57]. Although there may 
be specificities concerning the presentation of cranial GCA and LV-GCA, they are not 
distinct entities (Table 1). More likely, we are facing a different spectrum of the same 
disease (Figure 1). Depending on the different imaging techniques used, 32–83% 
of the patients with confirmed cranial GCA also have LV vasculitis [10–12, 14] and 
10–30% of the patients with GCA have only LV vasculitis, with no clinical, histologic 
or Doppler evidence of temporal artery vasculitis [10, 48, 58, 59].
Figure 1. 
The clinical spectrum of cranial GCA, LV-GCA and PMR.
Symptoms and signs Cranial GCA LV-GCA PMR
Headache ++ + —
Jaw claudication ++ — —
Visual disturbances ++ — —
Limb claudication + ++ —
Fever, night sweats, weight loss + ++ +
Polymyalgic symptoms + ++ ++
Peripheral arthralgia/arthritis + + ++
Elevation of inflammatory markers ++ ++ ++
GCA, Giant Cell Arteritis; LV, Large Vessel; PMR, Polymyalgia Rheumatica; −, uncommon symptom or sign;  
+, common symptom or sign; ++, very common symptom or sign.
Table 1. 
Clinical symptoms and signs in different subtypes of GCA and in PMR.
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Due to the more unspecific nature of the clinical presentation of LV-GCA, the 
diagnosis is often delayed or even missed. In general, patients with isolated LV-GCA 
have a delay in the diagnosis greater than one year compared with patients with cra-
nial GCA [7]. It is still unknown whether this delay in diagnosis and treatment may 
impact the clinical course of the disease. However, LV-GCA patients relapse more 
frequently and earlier than those with cranial GCA and have higher corticosteroid 
cumulative doses and more frequently require additional immunosuppressive treat-
ments [7, 54]. These facts suggest that patients with LV-GCA should be considered 
for a different management and treatment strategy, with a more tailored, eventually 
more aggressive approach.
4. Differential diagnosis
The systemic LV involvement in GCA may resemble the presentation of 
Takayasu arteritis (TAK). Patients with Takayasu’s disease may present with raised 
inflammatory markers, vascular bruits, asymmetric blood pressure measurements 
and limb claudication, much like patients with LV-GCA. The recent widening of 
the concept of vascular involvement in GCA shows that there can be an overlap 
between these two conditions. However, some have proposed clear distinctions. 
Most importantly, the epidemiology is quite different. GCA is recurrent among 
northern European patients, whereas TAK is more prevalent among the Asian 
population [60]. Another difference is the age of disease onset. GCA is almost 
exclusively present in patients 50 years or older, whereas TAK is common under 40 
[2, 61]. However, some argue age restriction to be arbitrary and without etiologic or 
pathophysiologic basis [20]. In a study of 96 Japanese patients with TAK, 22% were 
outside the proposed age cut-off [62]. Likewise, in the study that defined the 1990 
ACR Classification Criteria for GCA, 23% of the patients had less than 50 years old 
at diagnosis [6]. Moreover, these definitions are elusive for patients with LV vascu-
litis aged between 40 and 50 years. So, distinguishing GCA and TAK based only on 
age and epidemiology may be difficult suggesting that we might, in fact, be looking 
at two forms of the same disease [63].
The histopathologic findings in both GCA and TAK show a lymphohistiocytic 
infiltrate in the vascular wall that may be indistinguishable [20]. However, this 
observation may be biased due to the small number of patients undergoing vascular 
biopsy in TAK. Pathophysiologic mechanisms also show common features between 
both diseases [42, 46]. Clinically, TAK presents with a more widespread vascular 
involvement. The carotid and mesenteric arteries are more frequently affected in 
patients with TAK than GCA, while subclavian and axillary artery involvement is 
more prevalent in LV-GCA [63, 64]. The aortic involvement is also distinct since 
stenotic/occlusive lesions are predominant in TAK, whereas aneurysmal disease 
is more common in GCA [64]. It is unclear, however, if the differences in imaging 
findings represent cumulative damage due to delay in TAK diagnosis or whether 
other age-related immunologic and vascular factors may explain these differences. 
Lastly, inflammatory markers seem to be higher in patients with GCA than in TAK. 
Around 44% of the patients with TAK may have active vascular inflammation 
despite normal inflammatory marker values [65].
Several cases of small and medium vessel vasculitis have been described with 
temporal artery involvement, particularly granulomatosis with polyangiitis and 
eosinophilic granulomatosis with polyangiitis [66]. However, the presentation of 
ANCA-associated vasculitis with aortitis is extremely rare [67] and even more so in 
other forms of primary vasculitis.
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Other systemic diseases present with aortitis and may also be mistaken with 
LV-GCA (Table 2). Some infections like syphilis or sub-acute endocarditis may 
evolve with aortitis [68, 69]. In these cases, serologic and microbiologic studies 
often guide the diagnosis. Other immune-mediated diseases also have aortitis as 
a prominent clinical feature such as Behçets disease, IgG4-related disease, and 
Erdheim-Chester disease. These entities often have other distinctive organ involve-
ment and typical histologic findings pointing to a different diagnosis [69–71]. Also, 
in IgG4-related and Erdheim-Chester diseases, aortic involvement occurs as peri-
aortitis and retroperitoneal fibrosis which is different from vascular inflammation. 
Aortitis may also be a late complication of ankylosing spondylitis. It often involves 
de aortic root or the iliac periaortic peritoneum. It presents late in the disease, and 
articular symptoms often precede it by years. With recent advances in treatment, it 
is expected that it will become a less common manifestation of the disease [72].
5. Imaging features of large-vessel giant cell arteritis
Several imaging techniques have contributed to significant improvements in 
the assessment and management of LV-GCA, yet no single method is considered 
preferable (Table 3).
5.1 Ultrasonography
Ultrasonography has become widely used in GCA as it can be comparable to 
biopsy in the diagnosis of temporal arteritis [48, 73]. The presence of a regular 
hypoechoic non-compressible area around the lumen (the “halo sign”) that reflects 
an oedematous inflammatory intima-media thickening is considered diagnostic 
of medium and large vessel vasculitis [74]. It is distinguished from atherosclerotic 
plaques since atherosclerosis presents as irregular iso- or hyper-echoic extrusions. 
Ultrasonography identifies aspects compatible with LV-GCA in 29–48% of patients 
when axillary-subclavian arteries are systematically analysed, and this standard 
evaluation is particularly important as 13–33% of patients have LV-GCA in the 
absence of temporal involvement [10, 11, 48, 58, 59]. The identification in the axil-
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(with a local cut-off for IMT ≥1 mm) correctly identified LV-GCA (Figure 2) with a 
sensitivity and a specificity of close to 100% [75].
Ultrasonography has the advantage of being inexpensive, not using ionising 
radiation and can be readily accessible to use, as demonstrated in the implementa-
tion of fast track clinics [55, 57], though it requires experienced sonographers. 
Ultrasonography may also be useful in disease monitoring, as most patients show 
the disappearance of wall thickening over the course of steroid treatment [76]. This 
is why ultrasonographic signs are accurate for diagnosis purposes only within the 
first two weeks of corticosteroid treatment, losing sensitivity thereafter [74, 76], 
whilst thoracic aorta examination is not easily accessible by ultrasound.
5.2 Computed tomography
Computed tomography (CT) and CT angiography (CTA) are useful for LV imaging: 
they have a short scanning time yet allowing for a comprehensive vascular assessment, 
including the thoracic and abdominal aorta. Prospective studies of newly diagnosed 
Figure 2. 
Doppler ultrasonography of a right axillary artery in a patient with Large Vessel Giant Cell Arteritis. White 
line shows a smoothly increased hypo-echoic intima-media thickness of around 1.5 mm.





Ultrasonography • Hypoechoic wall thickening (halo) 29–48% [10, 
48, 58, 59]
2 weeks
CT and CTA • Circumferential wall thickening




MRI • Circumferential wall thickening
• T2 sequence enhanced wall oedema
~54% [82] —
18FDG-PET • Increase vascular 18FDG uptake 58–83% [14, 
49, 83]
10 days
CT, Computed tomography; CTA, CT angiography; MRI, magnetic resonance; 18FDG-PET, 8F-deoxyglucose positron 
emission tomography; −, unavailable data.
Table 3. 
Imaging methods in the diagnosis of large vessel inflammation in giant cell arteritis.
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GCA patients assessed by CTA have revealed LV involvement in 45–68% of subjects 
[12, 77, 78]. Typical findings of LV include circumferential wall thickening and vessel 
wall contrast enhancement. However, CTA findings may be attenuated by an as short as 
three-day course of corticosteroid treatment [12]. Nevertheless, up to 43% of patients 
still present significant arterial wall thickening one year after treatment [79]. The 
simultaneous assessment of aortic dilation and the adequate distinction between vas-
culitis and atherosclerosis, which appears as focal calcifications, are other advantages 
of CTA. Ionising radiation is of concern when repetitive evaluations are performed, but 
novel low-dose CTA techniques may reduce radiation exposure (Figure 3) [80].
5.3 Magnetic resonance
Magnetic Resonance (MRI) conveys a wide vascular assessment with vasculitis 
appearing as a mural thickening or wall oedema, enhanced in T2 sequences. High-
resolution MRI has been extensively used to assess temporal arteritis, but there is 
little experience with MRI in LV-GCA [13, 81, 82]. In contrast, and as MRI does not 
require iodinated contrast or ionising radiation, it has been exhaustively used for 
periodic assessment in younger patients with TAK [80].
5.4 Positron emission tomography
18FDG-PET has become widely used in LV-GCA as it allows broad vascular 
assessment of inflamed vascular territories that have an increased glucose 
metabolism. Accordingly, 58–83% of patients with GCA show LV involvement in 
18FDG-PET studies [14, 49, 83]. 18FDG-PET also has the advantage of suggesting 
possible differential diagnoses such as infectious or neoplastic disease. However, it 
is not as accurate in assessing vascular stenosis or occlusions and distinction with 
atherosclerotic plaques that also show increased vascular uptake may be trouble-
some in older patients. Furthermore, a consensus agreement regarding 18FDG-
PET criteria of LV vasculitis is lacking. 18FDG uptake equal to or greater than liver 
uptake on PET has been proposed as the best criterion of LV inflammation in GCA 
[84]. The vascular uptake in LV is also attenuated after three-day corticosteroid 
treatment but nevertheless, maintains an adequate sensitivity for diagnostic 
purposes. Notwithstanding, after ten days of treatment, sensitivity may diminish 
considerably (Figure 4) [85].
Figure 3. 
Computed tomography (CT) and CT angiography (CTA) revealing Large Vessel Vasculitis in Giant 
Cell Arteritis (GCA). Left image shows a CTA image with circumferential wall thickening >2 mm of 
the thoracic aorta. Central CTA image shows the extent of thoracic aorta wall thickening in the same 
patient, predominantly involving posterior wall. Right image reveals thoracic wall thickening in CT 





There are no studies specifically addressing the treatment of LV-GCA. As 
such, LV-GCA is currently managed in the same fashion of GCA. Corticosteroids 
remain the mainstay of treatment. Induction of remission should be started with 
40-60 mg/day of prednisone equivalent to suppress systemic and vascular inflam-
mation and prevent ischaemic complications such as blindness, and then followed 
by progressive tapering [2, 56, 86]. However, GCA relapses are frequent and 
corticosteroids account for significant complications. Therefore, adjunctive therapy 
should be considered in selected patients. Methotrexate (MTX) has been used as 
an adjunctive treatment with modest efficacy [87, 88]. TNF inhibitors have proven 
to be ineffective in GCA [89–91]. By contrast, the IL6-receptor blocker tocilizumab 
(TCZ) proved to be an effective and safe adjunctive therapy in GCA. Treatment 
with TCZ induced remission in over 50% of patients at 52 weeks, compared to less 
than 20% with placebo, and markedly reduced cumulative corticosteroid doses 
[92]. Recent results from real-life data corroborate the efficacy of TCZ shown in 
clinical trials [93].
There is some indirect evidence that LV vasculitis responds equally to standard 
treatment. This is corroborated by prospective imaging studies that show a decrease 
in LV inflammation over the course of treatment [76, 79, 85]. In a small study 
MTX was effective in corticosteroid-resistant LV-GCA [94]. However, it is widely 
accepted that patients with LV-GCA have a more relapsing disease course and 
receive higher doses of corticosteroids and more concomitant immunosuppressive 
therapy [7, 95].
In the GIACTA trial, 119 out of 251 patients included had evidence of LV vascu-
litis [96]. The outcomes measured did not include vascular imaging, and there is no 
sub-analysis directly aimed at patients with LV involvement. However, weekly TCZ 
was superior to biweekly TCZ or placebo in relapsing disease [92]. Being LV-GCA 
a more relapsing disease, it is possible that TCZ might be a preferred treatment 
option in this subgroup of patients [97].
Two other drugs have been studied in small GCA trials with data regard-
ing LV-GCA. Ustekinumab, an IL-12/IL-23-blocking monoclonal antibody, was 
Figure 4. 
18FDG-PET scans of Large vessel GCA. Left panel shows aortitis with involvement of the thoracic and 
abdominal aorta. Central panel shouws inflammatory uptake of the ascendeing aorta and subclavian arteries. 
Reight panel reveals inflammatory uptake of the aorta and common carotid arteries. Arrows reveal areas of 
increased vascular 8FDG uptake.
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prospectively studied in 25 patients with refractory GCA, 10 of them with LV-GCA 
shown on CTA. Eight of these ten patients had multiple image assessments, and 
all of them showed improvement of wall thickening including four that had a 
complete resolution of the lesions [98]. However, in another prospective open-
label trial with 13 patients with newly diagnosed or relapsing GCA, enrolment was 
prematurely closed due to lack of efficacy and high relapse rates [99]. Abatacept, an 
IgG1-CTLA4 fusion protein, was evaluated in a trial with 41 patients, (22% had LV 
vasculitis) and showed an improvement in relapse-free rate and duration of remis-
sion as compared to placebo [100]. Both these drugs need to be further evaluated in 
prospective and more extensive trials to further assess their efficacy.
Encouraging preliminary results were reported from a randomised controlled 
trial with mavrilumab, an anti-GM-CSF receptor α monoclonal antibody, which has 
shown sustained remission at week 26 in 83% of the patients, compared to 50% in 
the placebo group. These results were consistent across the different disease sub-
groups (final report is still pending) [101].
Another open question is whether current treatment significantly improves 
vascular remodelling and long-term LV-GCA complications such as aneurysms. 
The inhibition of both Jak1 and Jak2 may be a reasonable target to reduce the 
activation of the Th1 and Th17 pathways present in LV-GCA. Two Jak1 and Jak2 
inhibitors are currently under investigation in clinical trials: baricitinib and 
upadacitinib [102, 103].
7. Complications and prognosis
Vascular complications of LV-GCA include the formation of arterial stenosis, 
occlusions and aneurysms [15, 16]. Involvement of the aorta commonly occurs 
as dilation or aneurysm, as aortic stenosis is unlikely. Stenosis presents as limb 
claudication, involving more commonly the superior extremities, although the 
involvement of the inferior extremity is also possible [7, 47]. GCA patients are at 
an increased risk of developing aortic aneurysms/dissection or large artery stenosis 
(Figure 5). While stenosis mostly occur during the first year, the incidence of aortic 
aneurysms/dissection increases over the five years following the GCA diagnosis 
Figure 5. 
Computed tomography angiography showing ascending aortic dilation in a patient with Giant Cell Arteritis.
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[104]. In the long-term, 10–33% of the patients may develop aortic aneurysms/dis-
section and around 13% may develop large-artery stenosis [16, 104, 105].
Interestingly, aortic dilation is already present in 15% of the newly diagnosed 
GCA patients [12] with the thoracic aorta being the most commonly involved [105]. 
Aortic aneurysms are more frequently found among male patients with identified 
cardiovascular risk factors that include hypertension, dyslipidaemia and coronary 
artery disease [16, 17, 106]. It is unlikely that aortic aneurysms result from the 
persistent inflammatory activity as patients with aortic dilation/aneurysms were 
found to have lower serum acute-phase reactants and a lower relapse rate [17, 
105]. However, increased 18FDG uptake in the aorta on PET performed at the GCA 
diagnosis was associated with the subsequent development of aortic dilation [107, 
108]. It is thus conceivable that a strong inflammatory response at the beginning 
of the disease followed by remodelling vascular factors and hemodynamic factors 
(like hypertension), may be more relevant to the development of aortic dilation and 
aneurysms than a continuous inflammatory process.
Despite all the possible complications, the overall prognosis of GCA is good, with 
a mortality rate similar to the general population [109]. However, GCA is responsible 
for a significant morbidity. Around 64% of the patients will have at least on relapse 
[52] and up to 86% of patients will develop at least on steroid related-complication 
[110]. Initially it would be thought that LV-GCA patients would not contribute to an 
increased morbidity as they have fewer ischaemic cranial events that classically have 
been responsible for the most relevant morbidity associated with GCA [10, 11].
However, LV-GCA patients have a more relapsing disease-course, have higher 
corticosteroid cumulative doses, and require additional immunosuppressive 
treatments [7, 95]. Moreover, patients with LV inflammation are at increased 
risk of developing large-artery stenosis and aortic arch syndrome [54, 105, 106]. 
In fact, when compared to the general population, survival is decreased in GCA 
patients with an aortic aneurysm/dissection [104], confirming the negative 
impact the involvement of large arteries has on both mortality and morbidity 
 associated to GCA.
8. Conclusions
LV-GCA has been previously misregarded and underdiagnosed. However, there 
is consistent evidence confirming that large arteries are involved in around two-
thirds of patients with GCA and one-third of patients with PMR. Classification 
criteria are inadequate for LV-GCA. A revision of the current criteria is required in 
the near future. LV-GCA presents a more relapsing-disease course and an increased 
risk of vascular complications, with LV inflammation being responsible for a 
considerable increment in the morbidity and mortality associated to this condition. 
This chapter emphasises the importance of carefully considering the large artery 
aspects in the management and treatment of patients with GCA.
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